(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2(Date:9/3/2008)...ldren Studied. Wrong,Conclusions Reached., NIXA, ...for Disease,Control and Prevention (CDC) study rel...R vaccine and autism. The National Autism Associat...he growing public concern over a,vaccine-autism co...esign,and methodology., For years, parents have c...
(Date:9/3/2008)...ically infected Hepatitis C,patients strongly conf...008, - Study is the first to show a statisticall...t of therapeutic Hepatitis C vaccination, - Data...ond generation, vaccine formulated with Intercell... activation, VIENNA, Austria, S...
(Date:9/3/2008)...-- Panacea Pharmaceuticals,Inc. today announced t...ng,antibodies against human aspartyl (asparaginyl)...er biomarker and therapeutic target. These antibod...chusetts Institute of,Technology (MIT) and Panacea...r development of human cancer diagnostics and ther...
(Date:9/3/2008)...o Launch Progress and Adlea ...e Call Today at 11:30 am ET, SOUTH SAN FRANCISCO,...,Inc. (Nasdaq: ANSV ) announced today that the c...mercial and late-stage product development to,acce...l pain management,company. The company also provid...
Breaking Medicine Technology:CDC Misses Target With Flawed MMR/Autism Study 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 2Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 3Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 5American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 1American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 2American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 3American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 4American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 5American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 6American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 7American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 8American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 9American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 10American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 11American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 12American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 13AEterna Zentaris to Further Develop Three Follow up Multi targeted Cytotoxic Candidates to AEZS 112 as Potential Novel Cancer Treatment 1512 1AEterna Zentaris to Further Develop Three Follow up Multi targeted Cytotoxic Candidates to AEZS 112 as Potential Novel Cancer Treatment 1512 2AEterna Zentaris to Further Develop Three Follow up Multi targeted Cytotoxic Candidates to AEZS 112 as Potential Novel Cancer Treatment 1512 3AEterna Zentaris to Further Develop Three Follow up Multi targeted Cytotoxic Candidates to AEZS 112 as Potential Novel Cancer Treatment 1512 4BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP 1 Gene in Multiple Cancer Types 668 1BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP 1 Gene in Multiple Cancer Types 668 2Data Support use of SuperGens CLIMB Technology in Lead Development and Optimization 665 1Data Support use of SuperGens CLIMB Technology in Lead Development and Optimization 665 2Data Support use of SuperGens CLIMB Technology in Lead Development and Optimization 665 3... Nasalfent shows clinically meaningful pain relief..., READING, England, 7 June 2007 - Archimedes Pharm...eutical company, today,presented new clinical data...ive fentanyl citrate nasal spray aimed at providin...reakthrough cancer,pain. Data were presented at th...
...Orexigen(TM) is evaluating zonisamide SR as a nove..., SAN DIEGO, June 07, 2007 /PRNewswire-FirstCall/ ...utical company focused on the,treatment of central... obesity, today announced results from a Phase I t... novel, proprietary,sustained-release (SR) formul...
Other Medicine Technology:Archimedes Pharma Presents Positive Efficacy and Safety Data on,Nasalfent at European Association for Palliative Care Congress 2Archimedes Pharma Presents Positive Efficacy and Safety Data on,Nasalfent at European Association for Palliative Care Congress 3OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 2OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 3OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 4The Vitek is a completely automated instrument that offers Rapid results (with an average of 2 - 6 hour same day turnaround), random or batch processing and a quality control module. It is used for b
IDS Rapid One, a microbial identification system.
The Cogent Microbial Luminescence System (MLS) is a superior Rapid microbial detection system for UHT product screening combining proven technology of ATP-bioluminescence with unsurpassed hardware in
The SkanWasher 300 is an automatic 96-well microplate washer designed to give reliable, reproducible results, with no cross-contamination between wells, and no carryover from plate to plate. The wash
Medicine Products: